In The News - Business Wire, September 18, 2025 (Full Announcement)
NucleoBio and PreCheck Health Services Announce Strategic Collaboration to Advance Non-Invasive Prostate Cancer Testing
Prostac™
Pre-FDA approved, Prostac™ is a patented, straightforward and non-invasive molecular-based blood test for the early detection** of prostate cancer with nearly100% precision. ā
Prostac™ replaces the Prostate-Specific Antigen (PSA) test, and the additional expensive, intrusive diagnostic tests presently needed to more accurately diagnose prostate cancer, and helps eliminate unnecessary, and often harmful, overtreatments.
Prostac™ takes away the worry and stress of an uncertain prostate cancer diagnosis and gives men the peace of mind and the confidence to take control of their personal health and well-being.
** Note: Prostac™ is a better predictor of prostate cancer than PSA with better specificity, sensitivity and accuracy.
Prostac™ Test
Prostac® Diagnostic Lab Test
This test can be performed at a Physicians' office or healthcare facility. The Prostac™ Diagnostic Lab Test analyzes a drawn blood sample to: āāā
-
Detect if a man has prostate cancer and the aggressiveness of the cancer if detected.ā
āāā
-
Identify a man's predisposition to developing prostate cancer.
ā
-
āCategorize the diagnosed prostate cancer into a distinct risk group ranging from indolent to aggressive castration-resistant.
āā
-
Aid physicians in making better treatment decisions.
Prostac™ "Point-of-Service" Sample Collection Kit
The Prostac™ "Point-of-Service" (POS) Collection Kit is used to collect a patient's blood sample at home and to mail the sample securely to a NucleoBio designated laboratory for testing. ā
āā
-
āāāāāāPatient designates the Physician to whom NucleoBio sends the test results for the patient's consultation.
āā
-
āāāāCan be used to regularly test a man who has a predisposition to prostate cancer or who has been diagnosed with low grade (indolent) prostate cancer. āā